Barty Medical Secures Nearly RMB 200 Million in Series D Funding Ahead of IPO Filing

Recently, Zhejiang Barty Medical Technology Co., Ltd. (hereinafter referred to as “Barty Medical”) announced the completion of its Series D financing round, raising nearly RMB 200 million. The round was led by Oriental Capital Group, with co-investment from Zhejiang Province’s “4+1” Biopharmaceutical and High-End Medical Device Industry Fund, Yifeng Capital, Zhongyiren Capital, and individual industrial investors. Existing shareholder Junxingjian Capital continued to increase its investment, while Qifeng Capital provided financial support.

The proceeds from this financing round will be primarily allocated to the commercial promotion and accumulation of clinical evidence for Barty Medical’s globally leading third-generation constrained drug-coated balloons, the expansion and establishment of a new generation of intelligent manufacturing bases, and the research and development of subsequent innovative vascular interventional products. As a pan-vascular interventional platform enterprise, Barty Medical has achieved rapid commercialization of its product portfolio in recent years through the continuous launch of innovative products, comprehensive success in centralized volume-based procurement bids, and the expansion of overseas sales. Meanwhile, the company has initiated strategic financing to further accelerate its global business development and capitalization strategy.

Barty Medical, established in August 2015 and headquartered at the Hangzhou Biomedical Port in China, is dedicated to the research and development, manufacturing, and commercialization of innovative devices in the field of pan-vascular intervention. The company has been honored with titles such as National High-Tech Enterprise, National “Little Giant” Enterprise specializing in sophisticated and niche technologies, Zhejiang Provincial Research Institute for High-Performance Vascular Interventional Devices, and Zhejiang Provincial Emerging Technological Dragon Enterprise. Since its inception, Barty Medical has been driven by the dual engines of lean manufacturing and innovation-led development, deeply cultivating the vascular intervention sector. To date, it has obtained NMPA medical device registration certificates for 19 products in China, forming a comprehensive portfolio of vascular intervention solutions that encompass vascular access, lumen preparation, and “intervention without implantation” drug therapy. In the future, the company plans to launch multiple products that are first-of-their-kind globally and within China.